Dirt Devil vs Johnson & Johnson
Side-by-side comparison of AI visibility scores, market position, and capabilities
TTI-owned budget vacuum brand with $50M+ revenue; Versa 3-in-1 launch in 2024 targeting value floor care segment; Walmart exclusive models leverage TTI's global manufacturing scale alongside Milwaukee Tool, Ryobi, and Hoover sister brands.
About
Dirt Devil is an American cleaning appliance brand with origins in 1905, when the Royal Appliance Manufacturing Company introduced its first electric floor care products. The Dirt Devil name was established in 1984 with the launch of a compact handheld vacuum that became one of the best-selling cleaning appliances in US retail history, popularizing the lightweight supplemental vacuum category. The brand is now owned by Techtronic Industries (TTI), the Hong Kong-based conglomerate that also owns Milwaukee Tool, Ryobi, and Hoover — providing global manufacturing scale and retail distribution infrastructure.\n\nDirt Devil's lineup concentrates on the value floor care segment: upright vacuums, stick vacuums, handheld vacuums, and multi-surface cleaners priced for budget-conscious consumers. The Versa 3-in-1 convertible vacuum, launched in 2024, exemplifies the brand's versatile, affordable positioning for apartment dwellers and secondary vacuum users. Products are sold primarily through Walmart, Target, and Amazon, with Walmart-exclusive models representing a significant share of US volume. The brand generates $50 million or more in annual revenue competing against Bissell, Eureka, and Black+Decker.\n\nDirt Devil's competitive advantage combines strong brand heritage recognition — the Dirt Devil name carries high awareness from 1980s and 1990s household penetration — with TTI's manufacturing cost efficiency. While Dyson and Shark have captured premium share, the sub-$100 segment where Dirt Devil competes remains large, driven by first-time household formation and secondary vacuum purchases. Walmart exclusivity strategy ensures volume while TTI's scale manages margin.
FY2024 Sales: $88.8B (+4.3%) | Net Profit: $14.1B (+5.6%) | EPS: $5.79 | Adjusted EPS: $9.98 | FY2025 Guidance: Operational Sales Growth 2.5-3.5%, Adj EPS $10.75-$10.95 (+8.7% midpoint)
About
Johnson & Johnson is one of the world's largest healthcare companies, founded in 1886 by brothers Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson in New Brunswick, New Jersey, where the company remains headquartered. Established to manufacture ready-to-use surgical dressings at a time when post-operative infection was a leading cause of surgical mortality, J&J was built on the scientific principles of antiseptic surgery advocated by Joseph Lister. The company trades on the NYSE under ticker JNJ and has evolved over 135+ years from a consumer health products manufacturer into a focused MedTech and pharmaceutical enterprise, completing the spinoff of its consumer health segment (Kenvue) in 2023.\n\nJohnson & Johnson now operates through two segments: Innovative Medicine and MedTech. Innovative Medicine encompasses oncology, immunology, neuroscience, infectious disease, and cardiovascular pharmaceutical products — including blockbusters Darzalex, Stelara, Tremfya, and Rybrevant. The MedTech segment includes surgical robotics (Ottava platform in development), electrophysiology (Abiomed, Biosense Webster), orthopedics (DePuy Synthes), and surgery systems, serving hospitals and surgical centers worldwide. Following the Kenvue separation, J&J is a pure-play healthcare technology and pharmaceutical company with significantly higher growth and margin profiles than its historical blended consumer-pharma-medtech structure.\n\nJohnson & Johnson reported FY2024 sales of $88.8 billion, up 4.3% year over year, with net profit of $14.1 billion, up 5.6%. The company's Innovative Medicine segment continues to grow driven by oncology and immunology portfolio strength, while MedTech benefits from procedure volume recovery and robotic surgery adoption. J&J's scale, R&D pipeline depth, and global commercial infrastructure — spanning more than 60 countries — position it as one of the two or three most consequential healthcare enterprises globally, with a patent portfolio, clinical trial network, and regulatory expertise that are nearly impossible to replicate.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.